GW&K Investment Management LLC Acquires 963,159 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

GW&K Investment Management LLC increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 43.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,160,924 shares of the biotechnology company’s stock after buying an additional 963,159 shares during the period. GW&K Investment Management LLC owned about 1.50% of BioCryst Pharmaceuticals worth $24,655,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of BCRX. Larson Financial Group LLC grew its holdings in BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,267 shares during the last quarter. Focus Partners Wealth purchased a new position in BioCryst Pharmaceuticals in the third quarter worth $77,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares during the last quarter. Vestmark Advisory Solutions Inc. purchased a new position in BioCryst Pharmaceuticals in the third quarter worth $81,000. Finally, Envestnet Portfolio Solutions Inc. purchased a new position in BioCryst Pharmaceuticals in the fourth quarter worth $81,000. Institutional investors own 85.88% of the company’s stock.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 150,000 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the sale, the insider directly owned 400,703 shares of the company’s stock, valued at $3,666,432.45. The trade was a 27.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.80% of the stock is owned by company insiders.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $8.19 on Thursday. The firm has a market capitalization of $2.08 billion, a PE ratio of -4.60 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.07. The company’s fifty day moving average price is $8.96 and its 200-day moving average price is $8.10.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The company had revenue of $156.41 million for the quarter, compared to analysts’ expectations of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. BioCryst Pharmaceuticals’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period last year, the firm earned $0.20 earnings per share. As a group, research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.66 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on BCRX shares. Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Wedbush cut their price target on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Evercore started coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 price target on the stock. Needham & Company LLC cut their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Finally, Citizens Jmp lifted their price target on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, May 7th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $20.70.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.